PEN Stock Analysis: Penumbra | NYSE

Thrombectomy Systems, Access Catheters, Embolization Coils, Neurosurgical Tools

Total Rating 53

Safety 88

Buy Signal -0.65

Medical Devices
Industry Rotation: -10.5

Market Cap: 12.5B
Avg Turnover: 86.6M

Risk 3d forecast

Volatility8.16%

VaR 5^th Pctl1.26%

VaR vs Median-5.17%

Reward TTM

Sharpe Ratio0.76

Rel. Str. IBD44.4

Rel. Str. Peer Group47.1

Character TTM

Beta0.510

Beta Downside0.500

Hurst Exponent0.481

Drawdowns 3y

Max DD40.09%

CAGR/Max DD0.21

CAGR/Mean DD0.62

EPS (Earnings per Share)

EPS CAGR: 38.74%
EPS Trend: 95.9%

Last SUE: -4.00
Qual. Beats: -2

Revenue

Rev. CAGR: 15.46%
Rev. Trend: 99.7%

Last SUE: 0.00
Qual. Beats: 0

Warnings

P/E Ratio 78.1

Below Avwap Earnings

Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 10.9 years of data

Jan +7.7% 40

Feb -0.3% 2

Mar -0.7% 2

Apr -0.5% 2

May -2.0% 14

Jun +1.1% 24

Jul -0.1% 2

Aug +1.1% 11

Sep -1.4% 2

Oct -0.3% 2

Nov +3.5% 6

Dec +0.5% 8

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: PEN Penumbra

Penumbra, Inc. is a U.S.-based medical device company founded in 2004 and headquartered in Alameda, California. Listed on the NYSE since 2015 under the ticker PEN, the company operates within the Health Care Equipment sub-industry and develops, manufactures, and markets devices sold through direct sales organizations and distributors in the United States and internationally.

The companys product portfolio focuses primarily on vascular and neurovascular interventions, with three main franchises: thrombectomy systems (for the removal of blood clots, including the Indigo, Lightning, and CAT RX product lines), embolization products (for treating aneurysms and vascular lesions using coil and occlusion devices), and access products (guide and delivery catheters). It also offers neurosurgical tools such as the Artemis Neuro Evacuation Device.

As a medical device manufacturer, Penumbras business model is characterized by ongoing investment in product development and clinical evidence to support adoption of its technologies in hospital-based settings. The medical device sector is subject to regulatory oversight (such as FDA clearance in the U.S.) and reimbursement decisions by payers, both of which directly affect commercialization timelines and market access for new devices.

Headlines to Watch Out For

Lightning Flash and Bolt 7 drive vascular thrombectomy revenue growth
Inari Medical competition pressures vascular thrombectomy market share
Neurovascular stroke procedure volume drives U.S. revenue growth

Piotroski VR-10 (Strict) 7.0

Net Income: 160.6m TTM > 0 and > 6% of Revenue
FCF/TA: 0.11 > 0.02 and ΔFCF/TA 1.28 > 1.0
NWC/Revenue: 73.78% < 20% (prev 70.91%; Δ 2.88% < -1%)
CFO/TA 0.14 > 3% & CFO 277.8m > Net Income 160.6m
Net Debt (-446.1m) to EBITDA (222.3m): -2.01 < 3
Current Ratio: 5.75 > 1.5 & < 3
Outstanding Shares: last quarter (39.6m) vs 12m ago 0.83% < -2%
Gross Margin: 67.84% > 18% (prev 66.47%; Δ 1.37% > 0.5%)
Asset Turnover: 82.47% > 50% (prev 76.44%; Δ 6.03% > 0%)
Interest Coverage Ratio: 157.9 > 6 (EBIT TTM 205.1m / Interest Expense TTM 1.30m)

Altman Z'' 8.57

A: 0.56 (Total Current Assets 1.34b - Total Current Liabilities 233.8m) / Total Assets 1.97b
B: 0.15 (Retained Earnings 305.1m / Total Assets 1.97b)
C: 0.11 (EBIT TTM 205.1m / Avg Total Assets 1.82b)
D: 3.45 (Book Value of Equity 1.53b / Total Liabilities 444.0m)
Altman-Z'' = 8.57 = AAA

Beneish M -3.13

DSRI: 0.92 (Receivables 190.4m/175.5m, Revenue 1.50b/1.28b)
GMI: 0.98 (GM 66.47% / 67.84%)
AQI: 0.77 (AQ_t 0.15 / AQ_t-1 0.19)
SGI: 1.18 (Revenue 1.50b / 1.28b)
TATA: -0.06 (NI 160.6m - CFO 277.8m) / TA 1.97b)
Beneish M = -3.13 (Cap -4..+1) = AA

What is the price of PEN shares?

As of September 18, 2026, the stock is trading at USD 318.87 with a total of 416,059 shares traded. Over the past week, the price has changed by +0.34%, over one month by -2.54%, over three months by +0.86% and over the past year by +24.42%.

Current recommended Stop Loss: 314.30 (which is 1.4% or 2.1 ATR below the current price).

Is PEN a buy, sell or hold?

Penumbra has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy PEN.

StrongBuy: 12
Buy: 2
Hold: 4
Sell: 0
StrongSell: 0

What are the forecasts/targets for the PEN price?

Analysts Target Price	361.8	13.5%

Penumbra (PEN) - Fundamental Data Overview as of 12 September 2026

Market Cap USD = 12.5b (12.5b USD * 1.0 USD.USD)
P/E Trailing = 78.0786
P/E Forward = 55.5556
P/S = 8.3178
P/B = 8.2231
P/EG = 3.6012
Revenue TTM = 1.50b USD
EBIT TTM = 205.1m USD
EBITDA TTM = 222.3m USD
Long Term Debt = 20.7m USD (from longTermDebtTotal, last fiscal year)
Short Term Debt = 16.8m USD (from shortTermDebt, last quarter)
Debt = 212.7m USD (from shortLongTermDebtTotal, last quarter) (leases 212.7m already included)
Net Debt = -446.1m USD (calculated: Debt 212.7m - CCE 658.8m)
Enterprise Value = 12.1b USD (12.5b + Debt 212.7m - CCE 658.8m)
Interest Coverage Ratio = 157.9 (Ebit TTM 205.1m / Interest Expense TTM 1.30m)
EV/FCF = 55.91x (Enterprise Value 12.1b / FCF TTM 215.9m)
FCF Yield = 1.79% (FCF TTM 215.9m / Enterprise Value 12.1b)
FCF Margin = 14.35% (FCF TTM 215.9m / Revenue TTM 1.50b)
Net Margin = 10.67% (Net Income TTM 160.6m / Revenue TTM 1.50b)
Gross Margin = 67.84% ((Revenue TTM 1.50b - Cost of Revenue TTM 484.0m) / Revenue TTM)
Gross Margin QoQ = 67.93% (prev 67.62%)
Tobins Q-Ratio = 6.11 (Enterprise Value 12.1b / Total Assets 1.97b)
Interest Expense / Debt = 0.61% (Interest Expense 1.30m / Debt 212.7m)
Taxrate = 21.22% (43.2m / 203.8m)
NOPAT = 161.6m (EBIT 205.1m * (1 - 21.22%))
Current Ratio = 5.75 (Total Current Assets 1.34b / Total Current Liabilities 233.8m)
Debt / Equity = 0.14 (Debt 212.7m / totalStockholderEquity, last quarter 1.53b)
Debt / EBITDA = -2.01 (Net Debt -446.1m / EBITDA 222.3m)
Debt / FCF = -2.07 (Net Debt -446.1m / FCF TTM 215.9m)
Total Stockholder Equity = 1.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.80% (Net Income 160.6m / Total Assets 1.97b)
RoE = 11.09% (Net Income TTM 160.6m / Total Stockholder Equity 1.45b)
RoCE = 13.97% (EBIT 205.1m / Capital Employed (Equity 1.45b + L.T.Debt 20.7m))
RoIC = 9.61% (NOPAT 161.6m / Invested Capital 1.68b)
WACC = 7.66% (E(12.5b)/V(12.7b) * Re(7.78%) + D(212.7m)/V(12.7b) * Rd(0.61%) * (1-Tc(0.21)))
Discount Rate = 7.78% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 67.72 | Cagr: 0.21%
[DCF] Terminal Value 77.97% ; FCFF base≈194.2m ; Y1≈222.6m ; Y5≈327.6m
[DCF] Fair Price = 136.5 (EV 4.93b - Net Debt -446.1m = Equity 5.38b / Shares 39.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 95.95 | EPS CAGR: 38.74% | SUE: -4.0 | # QB: -2
Revenue Correlation: 99.71 | Revenue CAGR: 15.46% | SUE: -0.00 | # QB: 0
EPS current Quarter (2026-09-30): EPS=1.18 | Chg30d=-7.68% | Revisions=-29% | Analysts=7
EPS current Year (2026-12-31): EPS=4.79 | Chg30d=-3.48% | Revisions=-44% | GrowthEPS=+24.7% | GrowthRev=+13.5%
EPS next Year (2027-12-31): EPS=6.13 | Chg30d=-1.53% | Revisions=-22% | GrowthEPS=+28.1% | GrowthRev=+13.0%
[Analyst] Revisions Ratio: -42% (up=4, down=12)